Jpmorgan Chase & CO Milestone Pharmaceuticals Inc. Transaction History

Jpmorgan Chase & CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$1.67 - $3.39 $390,268 - $792,222	-233,694 Reduced 95.64%	10,662 $17,000
Q3 2023 Nov 14, 2023	SELL	$2.68 - $3.69 $7,522 - $10,357	-2,807 Reduced 1.14%	244,356 $757,000
Q2 2023 Aug 11, 2023	SELL	$2.85 - $4.4 $367,339 - $567,120	-128,891 Reduced 34.27%	247,163 $704,000
Q1 2023 May 11, 2023	BUY	$3.14 - $4.2 $145,476 - $194,586	46,330 Added 14.05%	376,054 $1.48 Million
Q4 2022 Feb 13, 2023	BUY	$3.53 - $9.5 $974,452 - $2.62 Million	276,049 Added 514.3%	329,724 $1.31 Million
Q3 2022 Nov 14, 2022	BUY	$5.86 - $9.43 $293,796 - $472,782	50,136 Added 1416.67%	53,675 $493,000
Q2 2022 Aug 11, 2022	SELL	$5.13 - $7.37 $51,510 - $74,002	-10,041 Reduced 73.94%	3,539 $21,000
Q1 2022 May 11, 2022	BUY	$4.1 - $8.24 $27,084 - $54,433	6,606 Added 94.72%	13,580 $87,000
Q4 2021 Feb 10, 2022	BUY	$5.47 - $7.13 $38,147 - $49,724	6,974 New	6,974 $46,000

28.6M

200

Ticker MIST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,010,900
Market Cap $55.8M
Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II cl...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.